JP2008518999A5 - - Google Patents

Download PDF

Info

Publication number
JP2008518999A5
JP2008518999A5 JP2007539549A JP2007539549A JP2008518999A5 JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5 JP 2007539549 A JP2007539549 A JP 2007539549A JP 2007539549 A JP2007539549 A JP 2007539549A JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
phenyl
optionally substituted
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007539549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518999A (ja
Filing date
Publication date
Priority claimed from EP04026441A external-priority patent/EP1655283A1/en
Application filed filed Critical
Publication of JP2008518999A publication Critical patent/JP2008518999A/ja
Publication of JP2008518999A5 publication Critical patent/JP2008518999A5/ja
Abandoned legal-status Critical Current

Links

JP2007539549A 2004-11-08 2005-11-08 11β−HSD1阻害剤 Abandoned JP2008518999A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026441A EP1655283A1 (en) 2004-11-08 2004-11-08 11beta-HSD1 Inhibitors
PCT/EP2005/011933 WO2006048330A1 (en) 2004-11-08 2005-11-08 11βετα-hsd1 inhibitors

Publications (2)

Publication Number Publication Date
JP2008518999A JP2008518999A (ja) 2008-06-05
JP2008518999A5 true JP2008518999A5 (US07928230-20110419-C00074.png) 2008-12-25

Family

ID=34927280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539549A Abandoned JP2008518999A (ja) 2004-11-08 2005-11-08 11β−HSD1阻害剤

Country Status (7)

Country Link
US (1) US20090069323A1 (US07928230-20110419-C00074.png)
EP (2) EP1655283A1 (US07928230-20110419-C00074.png)
JP (1) JP2008518999A (US07928230-20110419-C00074.png)
AT (1) ATE427932T1 (US07928230-20110419-C00074.png)
DE (1) DE602005013812D1 (US07928230-20110419-C00074.png)
DK (1) DK1814846T3 (US07928230-20110419-C00074.png)
WO (1) WO2006048330A1 (US07928230-20110419-C00074.png)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
BRPI0606256A2 (pt) 2005-01-05 2009-06-09 Abbott Lab inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074330A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2007067817A1 (en) * 2005-12-07 2007-06-14 Cv Therapeutics, Inc. Abca1 elevating compounds
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2007138112A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
US9422235B2 (en) 2006-12-19 2016-08-23 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CN101838227A (zh) * 2010-04-30 2010-09-22 孙德群 一种苯甲酰胺类除草剂的安全剂
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
WO2012051117A2 (en) * 2010-10-11 2012-04-19 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses
RU2612959C2 (ru) 2011-02-18 2017-03-14 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи Аминоиндановые соединения и их применение при лечении боли
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
ES2571577T3 (es) 2012-01-31 2016-05-26 Lilly Co Eli Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
TW201343629A (zh) 2012-01-31 2013-11-01 Lilly Co Eli 可作為mogat-2抑制劑之新穎芐磺醯胺衍生物
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
AU2013341584A1 (en) 2012-11-06 2015-04-30 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
MX2017014956A (es) 2015-06-03 2018-04-13 Squibb Bristol Myers Co Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
KR20200094734A (ko) 2017-09-22 2020-08-07 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 헤테로사이클릭 화합물
DK3697785T3 (da) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidazo-pyridine forbindelser som pad-inhibitorer
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CA3083374A1 (en) 2017-11-24 2019-05-31 Jubilant Episcribe Llc Heterocyclic compounds as prmt5 inhibitors
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
JP2022508945A (ja) 2018-10-22 2022-01-19 カデント セラピューティクス,インコーポレーテッド カリウムチャネルモジュレーターの結晶形態

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206219D0 (en) * 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
US20060058315A1 (en) * 2002-11-07 2006-03-16 Astrazeneca Ab 2-Oxo-ethanesulfonamide derivates

Similar Documents

Publication Publication Date Title
JP2008518999A5 (US07928230-20110419-C00074.png)
RU2500673C2 (ru) Гетероциклические ингибиторы мек и способы их применения
CA2502269A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2006510630A5 (US07928230-20110419-C00074.png)
Emmitte mGlu5 negative allosteric modulators: a patent review (2010–2012)
RU2454411C2 (ru) Производные хинолина
Phillips et al. Discovery of trifluoromethyl (pyrimidin-2-yl) azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy
RU2006134004A (ru) Производные гетероариламинопиразола, пригодные для лечения диабета
AR054848A1 (es) Agonistas del receptor de la hormona tiroidea
AR055015A1 (es) Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos.
AU2018253864A1 (en) Ferroportin-inhibitor salts
CA2593264A1 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2004536115A5 (US07928230-20110419-C00074.png)
RU2011102560A (ru) Соединение карбоновой кислоты
JP2010520893A5 (US07928230-20110419-C00074.png)
CA2522435A1 (en) Inhibitors of akt activity
JP2007507551A5 (US07928230-20110419-C00074.png)
JP2010523653A5 (US07928230-20110419-C00074.png)
ZA200606870B (en) Oxadiazolone derivatives as PPAR delta agonists
RU2006140796A (ru) Ингибиторы дпп-iv
KR20190020170A (ko) 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법
JP2011521938A5 (US07928230-20110419-C00074.png)
CA2626402A1 (en) Potassium channel inhibitors
TW200920361A (en) Compounds useful as medicaments
JP2017508795A5 (US07928230-20110419-C00074.png)